494 related articles for article (PubMed ID: 29649739)
1. Therapeutic journery of nitrogen mustard as alkylating anticancer agents: Historic to future perspectives.
Singh RK; Kumar S; Prasad DN; Bhardwaj TR
Eur J Med Chem; 2018 May; 151():401-433. PubMed ID: 29649739
[TBL] [Abstract][Full Text] [Related]
2. Nitrogen Mustards as Anticancer Chemotherapies: Historic Perspective, Current Developments and Future Trends.
Diethelm-Varela B; Ai Y; Liang D; Xue F
Curr Top Med Chem; 2019; 19(9):691-712. PubMed ID: 30931858
[TBL] [Abstract][Full Text] [Related]
3. Nitrogen Mustards as Alkylating Agents: A Review on Chemistry, Mechanism of Action and Current USFDA Status of Drugs.
More GS; Thomas AB; Chitlange SS; Nanda RK; Gajbhiye RL
Anticancer Agents Med Chem; 2019; 19(9):1080-1102. PubMed ID: 30834842
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy.
Atwell GJ; Yang S; Pruijn FB; Pullen SM; Hogg A; Patterson AV; Wilson WR; Denny WA
J Med Chem; 2007 Mar; 50(6):1197-212. PubMed ID: 17326614
[TBL] [Abstract][Full Text] [Related]
5. Alkylating Agents, the Road Less Traversed, Changing Anticancer Therapy.
Karati D; Mahadik KR; Trivedi P; Kumar D
Anticancer Agents Med Chem; 2022; 22(8):1478-1495. PubMed ID: 34382529
[TBL] [Abstract][Full Text] [Related]
6. Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT).
Springer CJ; Dowell R; Burke PJ; Hadley E; Davis DH; Blakey DC; Melton RG; Niculescu-Duvaz I
J Med Chem; 1995 Dec; 38(26):5051-65. PubMed ID: 8544182
[TBL] [Abstract][Full Text] [Related]
7. Proteomic analysis of DNA-protein cross-linking by antitumor nitrogen mustards.
Loeber RL; Michaelson-Richie ED; Codreanu SG; Liebler DC; Campbell CR; Tretyakova NY
Chem Res Toxicol; 2009 Jun; 22(6):1151-62. PubMed ID: 19480393
[TBL] [Abstract][Full Text] [Related]
8. The mechanism of guanine alkylation by nitrogen mustards: a computational study.
Polavarapu A; Stillabower JA; Stubblefield SG; Taylor WM; Baik MH
J Org Chem; 2012 Jul; 77(14):5914-21. PubMed ID: 22681226
[TBL] [Abstract][Full Text] [Related]
9. Discovery and Optimization of Novel Hydrogen Peroxide Activated Aromatic Nitrogen Mustard Derivatives as Highly Potent Anticancer Agents.
Chen W; Fan H; Balakrishnan K; Wang Y; Sun H; Fan Y; Gandhi V; Arnold LA; Peng X
J Med Chem; 2018 Oct; 61(20):9132-9145. PubMed ID: 30247905
[TBL] [Abstract][Full Text] [Related]
10. DNA-Dependent protein kinase activity correlates with clinical and in vitro sensitivity of chronic lymphocytic leukemia lymphocytes to nitrogen mustards.
Muller C; Christodoulopoulos G; Salles B; Panasci L
Blood; 1998 Oct; 92(7):2213-9. PubMed ID: 9746757
[TBL] [Abstract][Full Text] [Related]
11. Aziridinium ion ring formation from nitrogen mustards: mechanistic insights from ab initio dynamics.
Mann DJ
J Phys Chem A; 2010 Apr; 114(13):4486-93. PubMed ID: 20222705
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the Lonidamine Potentiated Effect of Nitrogen Mustard Alkylating Agents on the Systemic Treatment of DB-1 Human Melanoma Xenografts in Mice.
Nath K; Nelson DS; Putt ME; Leeper DB; Garman B; Nathanson KL; Glickson JD
PLoS One; 2016; 11(6):e0157125. PubMed ID: 27285585
[TBL] [Abstract][Full Text] [Related]
13. Cross-linking of the DNA repair protein Omicron6-alkylguanine DNA alkyltransferase to DNA in the presence of antitumor nitrogen mustards.
Loeber R; Michaelson E; Fang Q; Campbell C; Pegg AE; Tretyakova N
Chem Res Toxicol; 2008 Apr; 21(4):787-95. PubMed ID: 18324787
[TBL] [Abstract][Full Text] [Related]
14. Nitrogen mustard drug resistant B-cell chronic lymphocytic leukemia as an in vivo model for crosslinking agent resistance.
Bramson J; McQuillan A; Aubin R; Alaoui-Jamali M; Batist G; Christodoulopoulos G; Panasci LC
Mutat Res; 1995 May; 336(3):269-78. PubMed ID: 7739615
[TBL] [Abstract][Full Text] [Related]
15. Induction of apoptosis by the ADEPT agent ZD2767: comparison with the classical nitrogen mustard chlorambucil and a monofunctional ZD2767 analogue.
Monks NR; Blakey DC; Curtin NJ; East SJ; Heuze A; Newell DR
Br J Cancer; 2001 Sep; 85(5):764-71. PubMed ID: 11531265
[TBL] [Abstract][Full Text] [Related]
16. Modulation of the reactivity of nitrogen mustards by metal complexation: approaches to modify their therapeutic properties.
Karmakar S; Maji M; Mukherjee A
Dalton Trans; 2019 Jan; 48(4):1144-1160. PubMed ID: 30629051
[TBL] [Abstract][Full Text] [Related]
17. Improving the Potency of Cancer Immunotherapy by Dual Targeting of IDO1 and DNA.
Fang K; Dong G; Wang H; He S; Wu S; Wang W; Sheng C
ChemMedChem; 2018 Jan; 13(1):30-36. PubMed ID: 29205945
[TBL] [Abstract][Full Text] [Related]
18. DNA damage and mutagenesis induced by nitrogen mustards.
Povirk LF; Shuker DE
Mutat Res; 1994 Dec; 318(3):205-26. PubMed ID: 7527485
[TBL] [Abstract][Full Text] [Related]
19. DNA-directed alkylating agents. 1. Structure-activity relationships for acridine-linked aniline mustards: consequences of varying the reactivity of the mustard.
Gourdie TA; Valu KK; Gravatt GL; Boritzki TJ; Baguley BC; Wakelin LP; Wilson WR; Woodgate PD; Denny WA
J Med Chem; 1990 Apr; 33(4):1177-86. PubMed ID: 2319563
[TBL] [Abstract][Full Text] [Related]
20. Sequence selectivity, cross-linking efficiency and cytotoxicity of DNA-targeted 4-anilinoquinoline aniline mustards.
McClean S; Costelloe C; Denny WA; Searcey M; Wakelin LP
Anticancer Drug Des; 1999 Jun; 14(3):187-204. PubMed ID: 10500495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
